Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
Aymen Elfiky(Merck & Co., Inc., Rahway, NJ, USA (United States)), Harriet M. Kluger(Yale Cancer Center)
Cited by 51
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
|Journal of Clinical Oncology|2015|443
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2023|231
Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma
|Clinical Cancer Research|2009|72